CD276 and prostate cancer: Previous reports demonstrated the overexpression of B7-H3 in human malignancies, such as cutaneous melanoma [107], acute leukemia [108], breast cancer [109], prostate cancer [110], ovarian cancer [111], pancreatic cancer [112], colorectal cancer [113], GBM [114], and other cancers.